Issues related to the development and approval of therapies for rare diseases Pharmaceutical tariffs
2026 · 1st Quarter (Jan 1 - Mar 31)
HARMONY BIOSCIENCES
Filed by BROWNSTEIN HYATT FARBER SCHRECK, LLP.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 15, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- BROWNSTEIN HYATT FARBER SCHRECK, LLP
- Client
- HARMONY BIOSCIENCES
- Filing UUID
- 96ed98e7-4c39-421b-8544-6505a9f0b9f1
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.